Extended Data Figure 10. Effect of cytosolic DNA sensing pathways on prognosis.

a, Distant metastasis-free survival (DMFS), Relapse-free survival (RFS) and Progression-free survival (PFS) of breast and lung cancer patients, respectively stratified based on their expression of NF-κB and interferon pathways, significance tested using two-sided log-rank test. b, Disease-specific survival of mice injected with dnMCAK expressing MDA-MB-231 cells co-expressing either control shRNA, STING shRNA, NFKB2 shRNA, or RelB shRNA n = 35, 16, 19, and 20 mice in the control, STING shRNA, NFKB2 shRNA, and RelB shRNA groups respectively, significance tested using two-sided log-rank test. c, Number of MDA-MB-231 cells expressing shRNA targeting genes belonging to the DNA sensing or noncanonical NF-κB pathways that invaded through a collagen membrane within 24 hours of culture. Bars represent mean ± SD, ** p < 0.0001, two-sided Mann Whitney test, n = 20 high-power fields, 2 independent experiments. d, Number of different normal tissues (vascular, neuronal, or soft tissues) invaded by orthotopically transplanted tumors. Bars represent mean ± s.e.m., *p < 0.05, two-tailed t-test, n = 13 tumors (CIN-high), 20 tumors (noncanonical NF-κB depleted), 19 tumors (cGAS-STING depleted). e, Oncoprints showing genomic alterations in STING (TMEM173) and cGAS (MB21D1) in breast and lung cancers from the TCGA database.